Selecting appropriate therapy for a specific patient with cardiovascular disease requires markers of both disease severity and location to identify the risk of a clinical event. Classic markers, such as the Framingham Risk Score, identify a population at risk, but do not perform well for an individual patient. To get patient specific information at a reasonable cost will likely require a two-step process.
Step one would identify the presence of disease with an inexpensive laboratory assay; step two would be a non-invasive imaging technique to localize atheroma at risk of forming an occlusive thrombus. At this time we do not have a sensitive and specific screening blood test. There are, however, multiple imaging techniques that may provide information on the geographic distribution of lesions at moderate or high risk of rupture. PET/CT imaging can identify three markers that may be helpful for the imaging evaluation: 
Microcalcification (
18 F-fluoride localization in regions with either no CT detectable calcification or small foci of spotty calcification), appears to represent a specific phase in the evolution of an atheroma, when severe inflammation and necrosis begin to stabilize, and microcalcifications form in the necrotic core. This point in the life of the lesion may be a more specific indicator to identify risk for cardiovascular events than imaging inflammation, macrophage cell death [2] , or dense calcification [3] .
In a recently published manuscript Blomberg et al. [4] , challenge the role of measuring attenuation at the time of NaF PET/CT (using an attenuation threshold of 130 Hounsfield units). The calcium volume from all slices was summed and divided by the number of slices resulting in a single mean CT calcium volume (mm 3 ). The investigators report three major observations from this study: F-NaF uptake and thoracic aorta CT calcium burden, but not thoracic aorta 18 F-FDG uptake, were independent determinants of FRS. From these findings, the investigators concluded that thoracic aorta calcification, but not inflammation, is associated with increased cardiovascular disease risk.
The lack of correlation of vascular FDG uptake and FRS is surprising, and differs from the results of other investigators. Moon et al. [5] found a correlation of carotid FDG uptake and FRS, but not of carotid intima/media ratio, as a predictor of events during an average follow-up of 4.2 years. Similarly, Hetterich et al. [6] found a correlation of FDG vascular uptake with traditional risk factors. The discordance of findings by Blomberg et al. in the CAMONA study population and those of Moon and Hetterich primarily in cancer patients may be due to the difference in the study populations, or other factors. Atherosclerosis is a dynamic, ongoing process. Lesions evolve. Rudd et al. suggest the FDG uptake is stable during a 2 week interval [7] . Lesions evolve, however, from a low risk for causing a clinical event such as a fatty streak, to high risk when the lesion develops a large necrotic core, neovascularization and a thin cap. A high risk lesion may evolve to low risk, with development of a thick cap and a decrease in size of the necrotic core, usually associated with increased calcification within the lesion. Obtaining a 'snapshot' of the status of a dynamic lesion in a small population of patients can lead to erroneous conclusions. The evolution of an atheroma from low risk to high risk and back to low risk is summarized in Fig. 1 . The potential role of 18 F-FDG to detect vascular inflammation in atherosclerosis was proposed over 20 years ago [8] and has been well investigated compared to the relatively recent (∼6 year [1] ) literature on vascular 18 F-NaF uptake. 18 F-FDG imaging has been applied to demonstrate a decrease in carotid inflammation due to therapy with simvastatin [9] . Confounding these changes in FDG uptake is the waxing and waning course of inflammation in atheroma.
Endothelial cell
In spite of the short-term reproducibility of vascular FDG uptake, both Menezes LJ et al. [10] . and Meirelles et al. [11] confirmed that 18 F-FDG uptake changes over time, either increasing or decreasing in intensity and extent, reflecting the waxing and waning course of atheroma. On the other hand, calcification had only minimal changes over time, often increasing slightly over the interval between imaging. These changes are in keeping with the intravascular ultrasound findings described by Kubo et al. [12] and eloquently discussed by Arbab-Zadeh and Fuster in their landmark editorial in JACC [13] . The Kubo study determined that of 20 lesions classified as thin cap fibroatheroma on virtual histology intravascular ultrasound (VH-IVUS), 15 healed and five remained unchanged 1 year later.
Although 18 F-NaF was introduced by Blau et al. in 1962 [14] for detection of osseous metastasis, it was only recently proposed for the detection of vascular microcalcification by Derlin et al. [1] . Derlin et al. showed 18 F-NaF uptake is a surrogate marker of calcifying carotid plaque and only 6.5% of arterial lesions seen on the 18 F-fluoride images co-localized with 18 F-FDG, suggesting that 18 F-NaF and 18 F-FDG provide different information about atheroma [15, 16] . Aortic calcium is a known risk marker of CVD. Fiz F et al. investigated the relationship between the aortic calcium and 18 F-NaF uptake on atherosclerotic plaque on PET CT imaging and found greater 18 F-NaF uptake in the lowest density calcifications (<210 HU) than in medium calcifications (211-510 HU) and dense calcification (>510 HU). They suggested 18 F-NaF uptake reflects calcium deposition in the early stages of plaque formation [17] .
The surprising lack of correlation of FDG uptake and Framingham Risk Score in the Blomberg study needs to be confirmed in a follow-up study with more patients, evaluated at multiple time points, over several years. When we have that data, we will know whether FDG imaging, fluoride imaging or calcium score (or a combination of measurements) provide the most sensitive and specific prognostic information about cardiovascular events.
